Adebrelimab with Surgery for Stomach Cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a new immunotherapy drug called adebrelimab combined with chemotherapy and surgery for stomach cancer or junction cancers (where the stomach meets the esophagus). The goal is to see if this treatment helps prevent cancer from coming back after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with gastric cancer or gastroesophageal junction cancer confirmed by a biopsy
- You are between 18 and 75 years old
- Your doctor believes you are healthy enough for chemotherapy and surgery to remove the cancer
- You have a tumor tissue sample available from the past 6 months
- You are in good enough health to handle the treatment (ECOG score 0-1, meaning you can do most normal activities)
- You have not received any previous cancer treatment like chemotherapy, radiation, or immunotherapy for this cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining adebrelimab (an immunotherapy) with chemotherapy (XELOX) before and after surgery for stomach cancer that hasn't spread. The goal is to see if this approach helps shrink tumors and improves outcomes.
This trial tests a combination of two targeted drugs (adebrelimab and apatinib) with standard chemotherapy (SOX regimen) before surgery for gastric cancer that cannot be removed right away. The goal is to shrink the tumor enough to make surgery possible.
This study tests a combination of four drugs given before and after surgery for a type of stomach or throat-stomach cancer that can be removed. The drugs are adebrelimab (immunotherapy), nab-paclitaxel, oxaliplatin, and tegafur. The goal is to see if this combination works better than standard treatments.
This trial tests a combination of three drugs (Disitamab Vedotin, Toripalimab, and XELOX) given before and after surgery for gastric or gastroesophageal junction cancer. The goal is to see if this treatment helps shrink the tumor and prevent it from coming back.
This trial tests a combination of three drugs—adebrelimab (an immunotherapy), fruquintinib (a targeted therapy to cut off blood supply to the tumor), and a chemotherapy (paclitaxel or albumin-bound paclitaxel)—in people with advanced stomach/gastric cancer whose disease has worsened after one prior chemotherapy. The goal is to see if this new mix can help control the cancer.
This trial tests a new immunotherapy drug (serplulimab) combined with standard chemotherapy before surgery for patients with locally advanced stomach or gastroesophageal junction cancer. The goal is to see if this combination helps shrink the tumor and improve outcomes.
Hear when a new Locally Advanced Gastric or Gastroesophageal Junction Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.